CTLA4 and neoplasm: Given the appropriate conditions in the TME, it suggests that anti-CTLA-4 can promote anti-tumor immune responses by increasing Th1-like Tregs that positively correlate with granzyme B and/or IFN-γ producing CD8+ TILs [83].